Skip to main content
. 2014 Oct 6;10(4):342–347. doi: 10.3988/jcn.2014.10.4.342

Table 1.

Baseline characteristics of the controls and the rhEPO recipients in study II

graphic file with name jcn-10-342-i001.jpg

Data are mean±SD or n values.

*Chi-square test, Delta FS: the progression rate of the ALSFRS-R (equal to 48-the ALSFRS-R score at the time of inclusion).

ALSFRS-R: amyotrophic lateral sclerosis Functional Rating Scale-Revised, delta FS: difference of ALSFRS-R, rhEPO: recombinant human erythropoietin.